Why are pharmacy acquisition costs and consumer prescription drug price indices apparently diverging?
研究发现药房采购成本低于劳工统计局消费者价格指数，且仿制药批准多时背离更大；剔除仿制药上市前6个月数据可消除大部分差异。
Abstract Pharmacy acquisition costs for prescription ( R x ) drugs have been trending below levels implied by the Bureau of Labor Statistics' (BLS) Consumer Price Index for R x drugs, with the divergence higher when generic approvals are high. Dropping the first 6 months of generic sales from price indices calculated from pharmacy acquisition costs eliminates most of the difference between such indices and BLS indices.